Could a single drug shield kidneys during heart surgery?
NCT ID NCT07625553
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug R2R01 can prevent acute kidney injury in people at high risk who are having heart surgery with a heart-lung machine. Participants receive either R2R01 or a placebo before and after surgery. The goal is to see if the drug reduces kidney damage and related complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- R2R01 (a relaxin agonist)
- What this could lead to
- If successful, this could lead to a new way to prevent kidney damage after heart surgery, reducing complications and hospital stays.
- What could go wrong
- This is an early phase 2 trial, so the drug may not prove effective or safe. Possible side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
IRCSS San Raffaele
RECRUITINGMilan, 20132, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which emergency dialysis saves more lives? a new study investigates
- A simple sensor on the back could warn of kidney danger during heart surgery
- Can a common blood thinner be safe for ICU patients with liver issues?
- A urine test that could foresee kidney danger in the ICU
- Which citrate solution minimizes metabolic chaos in kidney therapy?
- A wearable sensor might spot kidney danger before it strikes